CR6581A - Pirrolcarboxamidas fundido, receptores cerebrales gaba - Google Patents

Pirrolcarboxamidas fundido, receptores cerebrales gaba

Info

Publication number
CR6581A
CR6581A CR6581A CR6581A CR6581A CR 6581 A CR6581 A CR 6581A CR 6581 A CR6581 A CR 6581A CR 6581 A CR6581 A CR 6581A CR 6581 A CR6581 A CR 6581A
Authority
CR
Costa Rica
Prior art keywords
gaba
receptors
compounds
cerebral
pirrolcarboxamidas
Prior art date
Application number
CR6581A
Other languages
English (en)
Inventor
Evan Webber Stephen
Albaugh Pamela
Shaw Kenneth
Hutchinson Alan
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of CR6581A publication Critical patent/CR6581A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K51/047—Benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos de pirrolocarboxamida sustituidos. Estos compuestos son agonistas, antagonistas o agonistas inversos, altamente selectivos, para receptores de GABA (A) cerebral o precursores de agonistas, antagonistas o angonistas inversos para receptores de GABA (A) cerebral y por lo tanto son utiles en el diagnostico y tratamiento de ansiedad, depresion, demencia de Alzheimer, desordenes en el sueno y crisis epileptica, sobredosis con medicamentos benzodiazepinicos y para mejorar la memoria. Tambien se proporcionan ademas composiciones farmaceuticas que incluyen composiciones farmaceuticas empacadas. Los compuestos de la invencion tambien son utiles como sondas para la localizacion de receptores de GABA (A) en muestras de tejido.
CR6581A 1999-08-31 2002-02-07 Pirrolcarboxamidas fundido, receptores cerebrales gaba CR6581A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15178999P 1999-08-31 1999-08-31
US38731199A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
CR6581A true CR6581A (es) 2004-03-31

Family

ID=26848974

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6581A CR6581A (es) 1999-08-31 2002-02-07 Pirrolcarboxamidas fundido, receptores cerebrales gaba

Country Status (25)

Country Link
US (1) US7109351B1 (es)
EP (1) EP1210328A1 (es)
JP (1) JP2003508385A (es)
KR (1) KR20020027613A (es)
CN (1) CN1372546A (es)
AP (1) AP2002002420A0 (es)
AU (1) AU7092800A (es)
BG (1) BG106459A (es)
BR (1) BR0013664A (es)
CA (1) CA2381553A1 (es)
CR (1) CR6581A (es)
CZ (1) CZ2002614A3 (es)
EA (1) EA200200188A1 (es)
EE (1) EE200200111A (es)
HR (1) HRP20020104A2 (es)
HU (1) HUP0202534A3 (es)
IL (1) IL147971A0 (es)
IS (1) IS6290A (es)
MX (1) MXPA02001709A (es)
NO (1) NO20020948L (es)
OA (1) OA12015A (es)
PL (1) PL354513A1 (es)
SK (1) SK2582002A3 (es)
TR (1) TR200200544T2 (es)
WO (1) WO2001016103A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014939A1 (en) * 1999-08-31 2005-01-20 Neurogen Corporation Fused pyrrolecarboxamides: GABA brain receptor ligands
EP1265857A1 (en) * 2000-03-13 2002-12-18 Eli Lilly And Company Sulfonamide derivatives
AU2001264932A1 (en) 2000-05-26 2001-12-11 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
JP2004508359A (ja) 2000-09-06 2004-03-18 ニューロゲン　コーポレイション アリール置換テトラヒドロインダゾール、及び、ｇａｂａ−ａ受容体に対するリガンドとしてのそれらの使用
MXPA03001951A (es) 2000-09-06 2003-10-15 Neurogen Corp Pirroliminas y pirazoliminas fusionadas substituidas.
US6861529B2 (en) * 2001-07-06 2005-03-01 Pfizer Inc Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives
WO2003066634A1 (en) 2002-02-07 2003-08-14 Neurogen Corporation Substituted fused pyrazolecarboxylic acid arylamides and related compounds
CN100418965C (zh) * 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ，エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
CA2566184A1 (en) * 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
WO2006010362A1 (de) * 2004-07-23 2006-02-02 Justus-Liebig-Universität Giessen Aminoadamantan-derivate, verfahren zu ihrer herstellung und ihre verwendung
MY150731A (en) * 2006-11-27 2014-02-28 Lundbeck & Co As H Heteroaryl amide derivatives
CA2707492A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
EP2320907A4 (en) * 2008-08-05 2012-09-05 Merck Sharp & Dohme THERAPEUTIC COMPOUNDS
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455943A (en) 1966-10-21 1969-07-15 American Cyanamid Co Certain 5,8-dihydro-beta-carbolines
US4075343A (en) 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
DE3029980A1 (de) 1980-08-08 1982-03-11 Boehringer Mannheim Gmbh, 6800 Mannheim Indolderivate und verfahren zu ihrer herstellung
JPS57123180A (en) * 1980-12-17 1982-07-31 Schering Ag 3-substituted beta-carboline, manufacture and psychotropic drug containing same
DE3147276A1 (de) 1981-11-28 1983-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von indolderivaten, deren verwendung als wertvolle zwischenprodukte und neue 4-hydroxyindole
DE3246932A1 (de) 1982-12-16 1984-06-20 Schering AG, 1000 Berlin und 4709 Bergkamen Substituierte 5h-pyrimido(5,4-b)indole
DE3335323A1 (de) 1983-09-27 1985-04-04 Schering AG, 1000 Berlin und 4709 Bergkamen Substituierte ss-carboline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8429739D0 (en) 1984-11-24 1985-01-03 Fbc Ltd Fungicides
DE3535927A1 (de) 1985-10-04 1987-04-09 Schering Ag 3-vinyl- und 3-ethinyl-ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
WO1992006094A1 (en) 1990-10-09 1992-04-16 Neurogen Corporation Certain cycloalkyl and azacycloalkyl pyrrolopyrimidines; a new class of gaba brain receptor ligands
US5243049A (en) 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
JPH07503970A (ja) 1992-02-19 1995-04-27 ジ・アップジョン・カンパニー ＣＮＳ活性を有する３−置換イミダゾ（１，５−ａ）−キノキサリン類およびキナゾリン類
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
WO1994017095A1 (en) 1993-01-29 1994-08-04 Ariad Pharmaceuticals, Inc. Analogs of receptor tyrosine activation motifs and therapeutic uses thereof
US5750702A (en) 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US6211365B1 (en) * 1996-01-19 2001-04-03 Neurogen Corporation Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US5804686A (en) 1996-01-19 1998-09-08 Neurogen Corporation fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
IT1287264B1 (it) * 1996-03-21 1998-08-04 Lino Crespan Freno perfezionato per pattini con ruote in linea
EP0888300A1 (en) * 1996-03-22 1999-01-07 Neurogen Corporation Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US5677309A (en) 1996-03-22 1997-10-14 Neurogen Corporation 1,2,4-triazolo 4,3-c! quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones; a new class of GABA brain receptor ligands
US5955465A (en) 1996-03-22 1999-09-21 Neurogen Corporation 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
PT1030838E (pt) 1997-11-13 2003-03-31 Pfizer Prod Inc Metodo de sintese de pirrolamidas

Also Published As

Publication number Publication date
KR20020027613A (ko) 2002-04-13
EP1210328A1 (en) 2002-06-05
PL354513A1 (en) 2004-01-26
EE200200111A (et) 2003-06-16
IL147971A0 (en) 2002-09-12
NO20020948L (no) 2002-02-28
US7109351B1 (en) 2006-09-19
MXPA02001709A (es) 2002-10-23
AP2002002420A0 (en) 2002-03-31
CA2381553A1 (en) 2001-03-08
AU7092800A (en) 2001-03-26
HUP0202534A3 (en) 2002-12-28
HUP0202534A2 (hu) 2002-11-28
IS6290A (is) 2002-02-27
BG106459A (bg) 2002-12-29
EA200200188A1 (ru) 2002-08-29
SK2582002A3 (en) 2003-02-04
BR0013664A (pt) 2002-05-14
HRP20020104A2 (en) 2004-02-29
CZ2002614A3 (cs) 2002-08-14
CN1372546A (zh) 2002-10-02
TR200200544T2 (tr) 2002-06-21
OA12015A (en) 2006-04-19
WO2001016103A1 (en) 2001-03-08
NO20020948D0 (no) 2002-02-27
JP2003508385A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
ATE289593T1 (de) Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
CR6581A (es) Pirrolcarboxamidas fundido, receptores cerebrales gaba
ATE307127T1 (de) 2,4-substituierte pyridinderivate
GT199800021A (es) Utilizacion de antagonistas de los receptores de canabinoides centrales para la preparacion de medicamentos.
ATE266655T1 (de) Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
ES2193391T3 (es) Antagonistas muscarinicos.
PA8493701A1 (es) Compuestos para tratar la obesidad
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
DE60130675D1 (de) Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
BR0107695A (pt) Tratamento de dano cerebral, espinhal e a nervos
ATE378043T1 (de) Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha- synuclein fibril krankheiten
ECSP034797A (es) DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA COMO ANTAGONISTAS II MGLUR2
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
BR9809071A (pt) Agentes farmacológicos
DE60042496D1 (de) Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien
BRPI0417520A (pt) 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida
BRPI0408956A (pt) emprego de derivativos de carbamazepina para o tratamento de agitação em pacientes com demência
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
BR9913348A (pt) Tratamento dos distúrbios da ansiedade

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)